JPH06298731A - Production of heterocyclic compound - Google Patents

Production of heterocyclic compound

Info

Publication number
JPH06298731A
JPH06298731A JP5085858A JP8585893A JPH06298731A JP H06298731 A JPH06298731 A JP H06298731A JP 5085858 A JP5085858 A JP 5085858A JP 8585893 A JP8585893 A JP 8585893A JP H06298731 A JPH06298731 A JP H06298731A
Authority
JP
Japan
Prior art keywords
formula
compound
group
compound expressed
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5085858A
Other languages
Japanese (ja)
Inventor
Takashi Kato
隆志 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Holdings Corp
Original Assignee
Fuji Photo Film Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Photo Film Co Ltd filed Critical Fuji Photo Film Co Ltd
Priority to JP5085858A priority Critical patent/JPH06298731A/en
Publication of JPH06298731A publication Critical patent/JPH06298731A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PURPOSE:To efficiently obtain a compound in which a substituted aryl group is introduced into the heterocyclic nucleus without using a carcinogen by condensing a halogen-substituted benzazole compound with an arylboronic acid compound in the presence of a palladium catalyst. CONSTITUTION:A halogen-substituted benzazole compound expressed by formula I [X is NR1 or CR2R3 (R1 to R3 are H, alkyl or aryl); R is H, alkyl or alkylthio; V1 to V4 are H or substituent group (at least one or more are Br)] reacts with an arylboronic acid compound expressed by formula II (V5 to V9 are H or substituent group) in the presence of a palladium catalyst {e.g. tetrakis[triphenylphosphine]palladium} to afford a compound in which a substituted aryl group expressed by formula III is introduced into the heterocyclic nucleus. For example, a compound expressed by formula IV is cited as the compound expressed by formula I and, e.g. a compound expressed by formula V is cited as the compound expressed by formula II. Furthermore, e.g. a compound expressed by formula VI is cited as the compound expressed by formula III. The compound expressed by formula II is useful as an intermediate and a raw material for functional compounds such as a sensitizing coloring matter for photosensitive materials, dye, laser dyes or medicines.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は複素環化合物の製造方法
に関するものである。
FIELD OF THE INVENTION The present invention relates to a method for producing a heterocyclic compound.

【0002】[0002]

【従来の技術】一般式(III) で表される複素環化合物
は、それ自体写真用添加剤として用いられるほか、感光
材料用増感色素、染料、レーザー色素、医薬品などの機
能性化合物の中間体、原料として有用である。一般式(I
II) で表される複素環化合物の合成法としては、従来、
以下に示したルートが知られている。2−メチル−5−
フェニルベンゾイミダゾールの合成ルート(ベルギー特
許第595,327号参照)
BACKGROUND OF THE INVENTION The heterocyclic compound represented by the general formula (III) is used as a photographic additive itself, and is also an intermediate compound of functional compounds such as sensitizing dyes for dyes, laser dyes and pharmaceuticals. It is useful as a body and raw material. General formula (I
The conventional synthetic method of the heterocyclic compound represented by II) is
The routes shown below are known. 2-methyl-5
Synthesis route of phenylbenzimidazole (see Belgian Patent No. 595,327)

【0003】[0003]

【化4】 [Chemical 4]

【0004】[0004]

【発明が解決しようとする課題】しかし、従来の合成ル
ートでは、2−メチル−5−フェニルベンゾイミダゾー
ルの合成の場合、出発原料に発癌性物質であるビフェニ
ルアミン(IARCでclass1に指定)を用いる必要があ
る。そこで、発癌性物質を使用することなく、かつ効率
的に置換アリール基を複素環核に導入できる一般式(II
I)で表される複素環化合物の合成法の開発が望まれてい
た。
However, in the conventional synthetic route, in the case of synthesizing 2-methyl-5-phenylbenzimidazole, a carcinogen biphenylamine (designated as class 1 by IARC) is used as a starting material. There is a need. Therefore, it is possible to efficiently introduce a substituted aryl group into a heterocyclic nucleus without using a carcinogen (II
Development of a synthetic method of the heterocyclic compound represented by I) has been desired.

【0005】本発明の目的は、有害物質を使用すること
なく、かつ効率的に置換アリール基を複素環核に導入で
きる一般式(III) で表される複素環化合物の合成法を提
供することにある。
An object of the present invention is to provide a method for synthesizing a heterocyclic compound represented by the general formula (III), which can efficiently introduce a substituted aryl group into a heterocyclic nucleus without using harmful substances. It is in.

【0006】[0006]

【課題を解決するための手段】本発明者らは、上記の従
来法の欠点を克服するため、種々検討を行なった結果、
パラジウム触媒を用いるアリールカップリング反応が有
効であることを見出した。即ち、本発明の前記の目的
は、下記一般式(I)で表される化合物と一般式(II)
で表されるホウ酸化合物をパラジウム触媒存在下縮合さ
せて一般式(III) で表される複素環化合物を合成するこ
とを特徴とする製造方法によって達成された。一般式
(I)
The inventors of the present invention have conducted various studies to overcome the above-mentioned drawbacks of the conventional method, and as a result,
It was found that the aryl coupling reaction using a palladium catalyst is effective. That is, the above object of the present invention is to provide a compound represented by the following general formula (I) and a compound represented by the general formula (II)
It was achieved by a production method characterized in that a boric acid compound represented by the formula (1) is condensed in the presence of a palladium catalyst to synthesize a heterocyclic compound represented by the general formula (III). General formula (I)

【0007】[0007]

【化5】 [Chemical 5]

【0008】式中、XはNR1 またはCR2 3 を表
す。R1 、R2 及びR3 は水素原子、アルキル基または
アリール基を表す。Rは水素原子、アルキル基またはア
ルキルチオ基を表す。V1 、V2 、V3 及びV4 は水素
原子または置換基を表すが、少なくとも1つ以上は臭素
原子である。一般式(II)
In the formula, X represents NR 1 or CR 2 R 3 . R 1 , R 2 and R 3 represent a hydrogen atom, an alkyl group or an aryl group. R represents a hydrogen atom, an alkyl group or an alkylthio group. V 1 , V 2 , V 3 and V 4 represent a hydrogen atom or a substituent, and at least one or more is a bromine atom. General formula (II)

【0009】[0009]

【化6】 [Chemical 6]

【0010】式中、V5 、V6 、V7 、V8 及びV9
水素原子または置換基を表す。一般式(III)
In the formula, V 5 , V 6 , V 7 , V 8 and V 9 represent a hydrogen atom or a substituent. General formula (III)

【0011】[0011]

【化7】 [Chemical 7]

【0012】式中、X、R1 〜R3 、R、V1 〜V9
上記記載のものと同義である。次に、上記一般式(I)
〜(III) で表される化合物を更に詳細に説明する。
In the formula, X, R 1 to R 3 , R and V 1 to V 9 have the same meanings as described above. Next, the above general formula (I)
The compounds represented by (III) to (III) will be described in more detail.

【0013】R1 、R2 およびR3 は水素原子、アルキ
ル基またはアリール基であり、好ましいアルキル基は、
炭素数18以下の無置換アルキル基(例えばメチル、エ
チル)及び置換アルキル基{置換基としてたとえばハロ
ゲン原子、アルコキシ基}であり、好ましいアリール基
は、炭素数18以下の無置換アリール基(例えばフェニ
ル、1−ナフチル)及び置換アリール基{置換基として
例えばハロゲン原子、アルコキシ基)である。Rは水素
原子、アルキル基またはアルキルチオ基であり、好まし
いアルキル基は、炭素数18以下の無置換アルキル基
(たとえばメチル、エチル、プロピル、ブチル、ペンチ
ル)及び置換アルキル基{置換基としてたとえばハロゲ
ン原子、シアノ基、スルホ基、アルコキシカルボニル
基、アルコキシ基、ヒドロキシ基、アリールオキシ基、
アシルオキシ基、アリール基、アシル基などが挙げられ
る}であり、好ましいアルキルチオ基は、炭素数18以
下の無置換アルキルチオ基(たとえばメチルチオ、エチ
ルチオ、プロピルチオ、ブチルチオ、ペンチルチオ)及
び置換アルキルチオ基{置換基としてたとえばハロゲン
原子、シアノ基、スルホ基、アルコキシカルボニル基、
アルコキシ基、ヒドロキシ基、アリールオキシ基、アシ
ルオキシ基、アリール基、アシル基などが挙げられる}
である。Rとしてさらに好ましくは、無置換アルキル基
(たとえばメチル、エチル、プロピル)及び無置換アル
キルチオ基(たとえばメチルチオ、エチルチオ、プロピ
ルチオ)である。
R 1 , R 2 and R 3 are a hydrogen atom, an alkyl group or an aryl group, and a preferred alkyl group is
An unsubstituted alkyl group having 18 or less carbon atoms (for example, methyl, ethyl) and a substituted alkyl group {eg, a halogen atom or an alkoxy group as a substituent}, and a preferable aryl group is an unsubstituted aryl group having 18 or less carbon atoms (for example, phenyl). , 1-naphthyl) and a substituted aryl group (eg, a halogen atom or an alkoxy group as a substituent). R is a hydrogen atom, an alkyl group or an alkylthio group, and preferred alkyl groups are unsubstituted alkyl groups having 18 or less carbon atoms (eg, methyl, ethyl, propyl, butyl, pentyl) and substituted alkyl groups (eg, a halogen atom as a substituent). , Cyano group, sulfo group, alkoxycarbonyl group, alkoxy group, hydroxy group, aryloxy group,
Acyloxy group, aryl group, acyl group and the like}, and preferable alkylthio groups include unsubstituted alkylthio groups having 18 or less carbon atoms (eg methylthio, ethylthio, propylthio, butylthio, pentylthio) and substituted alkylthio groups (as substituents For example, halogen atom, cyano group, sulfo group, alkoxycarbonyl group,
Examples include an alkoxy group, a hydroxy group, an aryloxy group, an acyloxy group, an aryl group, an acyl group, etc.}
Is. R is more preferably an unsubstituted alkyl group (eg methyl, ethyl, propyl) and an unsubstituted alkylthio group (eg methylthio, ethylthio, propylthio).

【0014】V1 、V2 、V3 及びV4 はそれぞれ水素
原子、ハロゲン原子(たとえば、ふっ素塩素、臭素)、
炭素数18以下のアルキル基{たとえばメチル、エチ
ル、プロピル、ブチル、ペンチル、置換アルキル基(置
換基としてたとえばハロゲン原子、シアノ基、スルホ
基、アルコキシカルボニル基、アルコキシ基、ヒドロキ
シ基、アリールオキシ基、アシルオキシ基、アリール
基、アシル基など)}、炭素数8以下のアシル基(たと
えばアセチル、ベンゾイル)、炭素数8以下のアシルオ
キシ基(たとえばアセチルオキシ)、炭素数8以下のア
ルコキシカルボニル基(たとえば、メトキシカルボニ
ル、エトキシカルボニル、ベンジルオキシカルボニ
ル)、カルバモイル基(たとえばカルバモイル、モルホ
リノカルバモイル)、スルファモイル基(たとえば、ス
ルファモイル、N,N−ジメチルスルファモイル)、カ
ルボキシ基、シアノ基、ヒドロキシ基、アミノ基、炭素
数10以下のアルコキシ基(たとえば、メトキシ、エト
キシ、ベンジルオキシ)、炭素数10以下のアルキルチ
オ基(たとえば、メチルチオ、エチルチオ)、炭素数5
以下のアルキルスルホニル基(たとえばメチルスルホニ
ル)、スルホン酸基、アリール基(たとえば、フェニ
ル、ナフチル)であり、V1 、V2 、V3 及びV4 の少
なくとも1つ以上は臭素原子である。また、ベンゼン環
と縮合環を形成してもよく、たとえばベンゼン環、ナフ
タレン環、ピリジン環、フラン環などが挙げられる。こ
れらは、更に置換されていてもよい。
V 1 , V 2 , V 3 and V 4 are each a hydrogen atom, a halogen atom (eg, fluorine chlorine, bromine),
Alkyl groups having 18 or less carbon atoms (for example, methyl, ethyl, propyl, butyl, pentyl, substituted alkyl groups (eg, a substituent such as a halogen atom, a cyano group, a sulfo group, an alkoxycarbonyl group, an alkoxy group, a hydroxy group, an aryloxy group, Acyloxy group, aryl group, acyl group, etc.), an acyl group having 8 or less carbon atoms (eg, acetyl, benzoyl), an acyloxy group having 8 or less carbon atoms (eg, acetyloxy), an alkoxycarbonyl group having 8 or less carbon atoms (eg, Methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl), carbamoyl group (eg carbamoyl, morpholinocarbamoyl), sulfamoyl group (eg sulfamoyl, N, N-dimethylsulfamoyl), carboxy group, cyano group, hydro Shi group, an amino group, number 10 an alkoxy group having a carbon (e.g., methoxy, ethoxy, benzyloxy), having 10 or less of the alkylthio group having a carbon (e.g., methylthio, ethylthio), carbon atoms 5
The following are alkylsulfonyl groups (for example, methylsulfonyl), sulfonic acid groups, and aryl groups (for example, phenyl and naphthyl), and at least one of V 1 , V 2 , V 3 and V 4 is a bromine atom. Further, it may form a condensed ring with a benzene ring, and examples thereof include a benzene ring, a naphthalene ring, a pyridine ring and a furan ring. These may be further substituted.

【0015】V5 、V6 、V7 、V8 及びV9 は、それ
ぞれ水素原子または置換基を表し、置換基としては
1 、V2 、V3 及びV4 の説明中に記載のものなどが
挙げられる。
V 5 , V 6 , V 7 , V 8 and V 9 each represent a hydrogen atom or a substituent, and the substituents are those described in the explanation of V 1 , V 2 , V 3 and V 4. And so on.

【0016】また、本発明の製造方法は一般式(I)〜
(III) で表される化合物が同位元素(たとえば、 2H、
3H、13C)を含有していても適用できる。以下に、一
般式(I)〜(III) で表される化合物の具体例を示す
が、本発明はこれらに限定されるものではない。
Further, the production method of the present invention is represented by the general formula (I):
The compound represented by (III) is an isotope (for example, 2 H,
It can be applied even if it contains 3 H, 13 C). Specific examples of the compounds represented by formulas (I) to (III) are shown below, but the invention is not limited thereto.

【0017】[0017]

【化8】 [Chemical 8]

【0018】[0018]

【化9】 [Chemical 9]

【0019】[0019]

【化10】 [Chemical 10]

【0020】[0020]

【化11】 [Chemical 11]

【0021】[0021]

【化12】 [Chemical 12]

【0022】[0022]

【化13】 [Chemical 13]

【0023】[0023]

【化14】 [Chemical 14]

【0024】[0024]

【化15】 [Chemical 15]

【0025】本発明において触媒として用いるパラジウ
ム触媒としては、テトラキス〔トリフェニルホスフィ
ン〕パラジウム(Pd(PPh3)4)、酢酸パラジウム(Pd(OAc)
2)、塩化パラジウム(PdCl2) 、塩化ビス(ジフェニルホ
スフィノフェロセン)パラジウム(PdCl2〔bis(diphenyl
phosphino)ferrocene 〕)などが挙げられる。パラジウ
ムの価数は0であっても+2であってもよい。用いるパ
ラジウム触媒の当量数は、等量であっても触媒量であっ
てもよいが、0.01mol %〜10.0mol %が好まし
く、特に0.10mol %〜5.0mol%がより好まし
い。
Examples of the palladium catalyst used as a catalyst in the present invention include tetrakis [triphenylphosphine] palladium (Pd (PPh 3 ) 4 ) and palladium acetate (Pd (OAc)).
2 ), palladium chloride (PdCl 2 ), bis (diphenylphosphinoferrocene) palladium chloride (PdCl 2 [bis (diphenyl
phosphino) ferrocene]) and so on. The valence of palladium may be 0 or +2. The equivalent number of the palladium catalyst used may be an equivalent amount or a catalytic amount, but is preferably 0.01 mol% to 10.0 mol%, and more preferably 0.10 mol% to 5.0 mol%.

【0026】反応条件は、塩基の存在下で行なうことが
好ましく、塩基として炭酸ナトリウム、トリエチルアミ
ン、水酸化ナトリウム、ナトリウムメトキシド(NaOMe)
などを用いることができる。反応条件については、以下
の文献を参照することができる。 文献(a) 鈴木他、シンセチック・コミュニケーション(S
ynthetic Communication) 第11巻、第513 〜519 頁(19
81年)。 文献(b) ヴイ・スニーカス(V.Snieckus)他、テトラヘド
ロン・レターズ(Tetrahedron Letters) 第28巻、第5093
〜5096頁(1987年)。
The reaction conditions are preferably carried out in the presence of a base, such as sodium carbonate, triethylamine, sodium hydroxide, sodium methoxide (NaOMe) as the base.
Etc. can be used. For the reaction conditions, the following documents can be referred to. Reference (a) Suzuki et al., Synthetic Communication (S
Synthetic Communication) Vol. 11, pp. 513-519 (19
81 years). Reference (b) V. Snieckus et al., Tetrahedron Letters 28, 5093
~ 5096 pages (1987).

【0027】反応温度は、20℃から150℃までの間
が好ましく、反応温度が20℃より低い場合、反応の進
行が遅くなることがある。特に好ましくは、60℃から
120℃の間である。
The reaction temperature is preferably 20 ° C. to 150 ° C. When the reaction temperature is lower than 20 ° C., the progress of the reaction may be delayed. Particularly preferably, it is between 60 ° C and 120 ° C.

【0028】反応系としては、水−有機溶媒の2相系、
含水有機溶媒あるいは有機溶媒の均一系いずれであって
もよい。有機溶媒としては、トルエン、キシレン、ヘキ
サンなどの炭化水素系溶媒、ジメチルホルムアミドなど
のアミド系溶媒、テトラハイドロフランなどのエーテル
系溶媒、メタノール、エタノールなどのアルコール系溶
媒、アセトニトリルなどのニトリル系溶媒アセトンなど
のケトン系溶媒、酢酸エチルエステルなどのエステル系
溶媒などを用いることができる。また、2種類以上の有
機溶媒を混合して用いてもよい。
The reaction system is a water-organic solvent two-phase system,
It may be either a water-containing organic solvent or a homogeneous system of organic solvent. Examples of the organic solvent include hydrocarbon solvents such as toluene, xylene and hexane, amide solvents such as dimethylformamide, ether solvents such as tetrahydrofuran, alcohol solvents such as methanol and ethanol, nitrile solvents such as acetonitrile, and acetone. A ketone-based solvent such as, an ester-based solvent such as ethyl acetate, and the like can be used. Further, two or more kinds of organic solvents may be mixed and used.

【0029】[0029]

【実施例】次に本発明を実施例に基づき更に詳細に説明
する。 実施例1.化合物(III−1)の合成
EXAMPLES The present invention will be described in more detail based on examples. Example 1. Synthesis of compound (III-1)

【0030】[0030]

【化16】 [Chemical 16]

【0031】窒素雰囲気下、化合物(I−1)0.23
gをトルエン5mlに溶解させ、Pd(PPh3)4 34mg(3mo
l %)、2規定の炭酸ナトリウム水溶液5ml、化合物
(II−1)0.15gのメタノール溶液5mlをこの順序
で加えた。反応液を外温85℃で2時間加熱攪拌した。
反応液を冷却後、塩化メチレンで反応生成物を抽出した
のち、塩化メチレンを留去した。得られた残査をシリカ
ゲルカラムクロマトグラフィー(溶離液:塩化メチレ
ン)で精製し、化合物(III−1)0.22gを得た。収
率98%、融点178〜182℃ 実施例2.化合物(III−3)の合成
Compound (I-1) 0.23 under nitrogen atmosphere
g was dissolved in 5 ml of toluene, and 34 mg of Pd (PPh 3 ) 4 ( 3 mo
1%), 5 ml of a 2N aqueous sodium carbonate solution and 5 ml of a methanol solution of 0.15 g of the compound (II-1) were added in this order. The reaction solution was heated and stirred at an external temperature of 85 ° C. for 2 hours.
After cooling the reaction solution, the reaction product was extracted with methylene chloride, and then methylene chloride was distilled off. The obtained residue was purified by silica gel column chromatography (eluent: methylene chloride) to obtain 0.22 g of compound (III-1). Yield 98%, melting point 178-182 ° C Example 2. Synthesis of compound (III-3)

【0032】[0032]

【化17】 [Chemical 17]

【0033】化合物(I−1)0.44gと化合物(II
−2)0.40gから実施例1.と同様の操作により、
化合物(III−3)0.40gを得た。収率80%以上の
結果より、本発明の合成法は収率よく目的とする一般式
(III) で表される化合物を与えることがわかる。また、
5位Ph基の導入を行なう際、従来法ではビフェニルア
ミンあるいはベンゼンなどの発癌性物質を用いる必要が
あるのに対し、本発明ではフェニルホウ酸を用いて合成
することができる点で有利である。
0.44 g of compound (I-1) and compound (II
-2) 0.40 g to Example 1. By the same operation as
0.40 g of compound (III-3) was obtained. From the result of the yield of 80% or more, the synthetic method of the present invention can be obtained in a high yield with the desired general formula.
It can be seen that it gives the compound represented by (III). Also,
When introducing the Ph group at the 5-position, a carcinogenic substance such as biphenylamine or benzene needs to be used in the conventional method, while the present invention is advantageous in that it can be synthesized using phenylboric acid.

【0034】[0034]

【発明の効果】本発明の合成法は、一般式(III) で表さ
れる化合物を収率よく与え、また従来法では発癌性物質
を用いる必要のある化合物を安全性の高い化合物から容
易に合成できる点で従来法よりも優れている。
INDUSTRIAL APPLICABILITY The synthetic method of the present invention gives a compound represented by the general formula (III) in a high yield, and in the conventional method, a compound requiring the use of a carcinogenic substance can be easily converted from a highly safe compound. It is superior to the conventional method in that it can be synthesized.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 ハロゲン置換ベンゾアゾール化合物とア
リールホウ酸化合物をパラジウム触媒存在下縮合させて
アリール置換ベンゾアゾール化合物を合成することを特
徴とする複素環化合物の製造方法。
1. A method for producing a heterocyclic compound, which comprises synthesizing an aryl-substituted benzoazole compound by condensing a halogen-substituted benzoazole compound and an aryl boric acid compound in the presence of a palladium catalyst.
【請求項2】 下記一般式(I)で表される化合物と一
般式(II) で表されるホウ酸化合物をパラジウム触媒存
在下縮合させて一般式(III) で表される複素環化合物を
合成することを特徴とする複素環化合物の製造方法。一
般式(I) 【化1】 式中、XはNR1 またはCR2 3 を表す。R1 、R2
及びR3 は水素原子、アルキル基またはアリール基を表
す。Rは水素原子、アルキル基またはアルキルチオ基を
表す。V1 、V2 、V3 及びV4 は水素原子または置換
基を表すが、少なくとも1つ以上は臭素原子である。一
般式(II) 【化2】 式中、V5 、V6 、V7 、V8 及びV9 は水素原子また
は置換基を表す。一般式(III) 【化3】 式中、X、R1 〜R3 、R、V1 〜V9 は上記記載のも
のと同義である。
2. A heterocyclic compound represented by the general formula (III) is obtained by condensing a compound represented by the following general formula (I) with a boric acid compound represented by the general formula (II) in the presence of a palladium catalyst. A method for producing a heterocyclic compound, which comprises synthesizing. General formula (I) In the formula, X represents NR 1 or CR 2 R 3 . R 1 and R 2
And R 3 represents a hydrogen atom, an alkyl group or an aryl group. R represents a hydrogen atom, an alkyl group or an alkylthio group. V 1 , V 2 , V 3 and V 4 represent a hydrogen atom or a substituent, and at least one or more is a bromine atom. General formula (II) In the formula, V 5 , V 6 , V 7 , V 8 and V 9 represent a hydrogen atom or a substituent. General formula (III): In the formula, X, R 1 to R 3 , R and V 1 to V 9 have the same meanings as described above.
JP5085858A 1993-04-13 1993-04-13 Production of heterocyclic compound Pending JPH06298731A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5085858A JPH06298731A (en) 1993-04-13 1993-04-13 Production of heterocyclic compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5085858A JPH06298731A (en) 1993-04-13 1993-04-13 Production of heterocyclic compound

Publications (1)

Publication Number Publication Date
JPH06298731A true JPH06298731A (en) 1994-10-25

Family

ID=13870582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5085858A Pending JPH06298731A (en) 1993-04-13 1993-04-13 Production of heterocyclic compound

Country Status (1)

Country Link
JP (1) JPH06298731A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100680428B1 (en) * 2003-09-29 2007-02-08 주식회사 하이닉스반도체 Photoresist Polymer and Photoresist Composition Containing it
KR100680427B1 (en) * 2003-07-30 2007-02-08 주식회사 하이닉스반도체 Photoresist Polymer and Photoresist Composition Containing it
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
US9290517B2 (en) 2012-08-22 2016-03-22 Merck Sharp & Dohme Corp. Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
US9556193B2 (en) 2012-08-22 2017-01-31 Merck Shapr & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9834563B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100680427B1 (en) * 2003-07-30 2007-02-08 주식회사 하이닉스반도체 Photoresist Polymer and Photoresist Composition Containing it
KR100680428B1 (en) * 2003-09-29 2007-02-08 주식회사 하이닉스반도체 Photoresist Polymer and Photoresist Composition Containing it
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9290517B2 (en) 2012-08-22 2016-03-22 Merck Sharp & Dohme Corp. Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
US9556193B2 (en) 2012-08-22 2017-01-31 Merck Shapr & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9834563B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds

Similar Documents

Publication Publication Date Title
JPH06298731A (en) Production of heterocyclic compound
CN109912606B (en) Synthesis method of pyrimido indazole compound
CN113121462A (en) Preparation method of 5-trifluoromethyl substituted 1,2, 3-triazole compound
CN111704582A (en) Preparation method of Favipiravir and derivatives thereof
CN108863890B (en) 4-pyrroline-2-ketone derivative and preparation method thereof
CN112778317B (en) Synthetic method of [1,2,4] triazolo [1,5-a ] pyrimidine compound
JP2802706B2 (en) Method for producing heterocyclic compound
Kiehne et al. Synthesis of 2, 8-disubstituted analogues of Tröger’s Base
CN111362795B (en) Preparation method of substituted butyrate derivatives
Sanivarapu et al. Synthesis and anti-inflammatory activity of 1, 2-3-substituted 2a1, 4, 5-triazacyclopenta [cd] indene derivatives
CN109053631B (en) Synthetic method for synthesizing benzo [1,3] oxazine-2-thioketone through isothiocyanate and 2-sulfonyl alkyl phenol
JP2006188582A (en) New pyrazolone compound and merocyanine coloring matter using it
Xue et al. A Novel Synthesis of Spiro (imidazolidine-2, 3′-benzo [b] thiophene) by One-Pot Reaction of Arynes, Aryl Isothiocyanates and N-Heterocyclic Carbenes
Kumar et al. An efficient approach to the synthesis of 4H-1-benzothiopyran-4-ones via intramolecular Wittig reaction
CN112125843B (en) Preparation method of 3-hydroxymethyl-4-phenyl-3, 4-dihydroquinolinone compound
KR102598580B1 (en) Novel method for preparing nitroalkene compounds
Kawazoe et al. Diverse Synthesis of 2H‐Isoindole‐Based Polycyclic Aromatic Compounds
Kumbhar et al. Synthesis of quinoxalines and pyrido [2, 3-b] pyrazines by Suzuki–Miyaura cross-coupling reaction
JP5208928B2 (en) C2-ruthenocene bisphosphine ligand having only symmetric planar chirality and its synthesis method
JP2001031656A (en) Production of heterocyclic compound
JP2001261646A (en) Method for producing pyridine derivative
CN117567360A (en) Chiral fluorine-containing quaternary carbon center compound and synthesis method thereof
KR880001850B1 (en) Preparation process for derivertives of 5-fluoro pyridone
CN116082336A (en) Preparation method for synthesizing multifunctional indolizine derivative by copper catalysis
CN117945824A (en) Deuterated methyl enaminone compound and preparation method thereof